Senior Pharmaceutical & Technology Executive and Current SVP, Chief Information Officer, North America at Kyowa Kirin International plc., Previously of IBM, Schering-Plough, Merck and Gilead Joins Entheon’s Advisory Board

Vancouver, BC – March 3, 2021 – Entheon Biomedical Corp. (CSE: “ENBI”; OTC: “ENTBF”; FSE: “1XU1”) (“Entheon” or the “Company”), a biotechnology company focused on developing psychedelic medicines to treat addiction, is pleased to announce Nancy Maher as Special Advisor of Data Science and Regulatory Affairs, providing expertise on the development of the Company’s data strategy design; study design; and advise on regulatory relationships and data strategy.

Ms. Maher has served as an executive and consultant for major pharmaceutical and information technology companies, including IBM, Gilead, Schering-Plough, Merck, Allergan, and Teva Pharmaceuticals. Ms. Maher is currently SVP, Chief Information Officer, North America of Kyowa Kirin International plc., and joins Entheon as its Special Advisor of Data Science and Regulatory Affairs.

Ms. Maher will be consulting on the development and implementation of Entheon’s data management systems for the collection, organization and analysis of data from upcoming pre-clinical and clinical trials, partnership initiatives, private clinic partnerships, and various technological initiatives. In addition, Ms. Maher will inform the Company of best practices for the design and implementation of security measures as they relate to the company’s data program, while also informing regulatory strategy and relationship as it relates to advancing conversations and applications with Health Canada, the FDA and EMA regulatory authorities.

“We would like to extend a warm welcome to Ms. Nancy Maher, who brings a wealth of experience and industry knowledge to Entheon. Ms. Maher understands the importance of data with regard to future product development and in characterizing the unique variables of diagnosis and drug response in patient populations, and we are thrilled to have access to her unique expertise,” said Chief Executive Officer Timothy Ko.

About Entheon Biomedical Corp.

Entheon is a biotechnology research and development company committed to developing and commercializing a portfolio of safe and effective N,N-dimethyltryptamine based psychedelic therapeutic products (“DMT Products”) for the purposes of treating addiction and substance use disorders. Subject to obtaining all requisite regulatory approvals and permits, Entheon intends to generate revenue through the sale of its DMT Products to physicians, clinics and licensed psychiatrists in the United States, certain countries in the European Union and throughout Canada.

About HaluGen Life Sciences Inc.

A global IT leader with significant experience in utilizing and enabling technology to deliver efficiency, productivity, quality and solutions for patients and the public health sector, Nancy has an extensive background in digital technology, big data and data analytics, as well as M&As. With more than 20 years of industry experience, including significant leadership roles at Gilead, Allergan, Teva, Merck, Schering-Plough, and IBM, Nancy currently serves as Senior Vice-President, Chief Information Officer of Kyowa Kiran NA, where she is establishing the company’s global digital and technology strategy.